MOGN and MethylGene initiate Phase II trial with MG98

MGI Pharma (MOGN) and MethylGene (Montreal, Quebec) started a Phase II trial in the U.S. and Canada using MG98, a DNA methyltransferase inhibitor, to treat head and neck squamous cell cancer. They exp...